Jan. 13 (Bloomberg) -- Roche Holding AG’s Genentech Inc. is facing the first trial of patients’ claims that its withdrawn Raptiva psoriasis drug spawned fatal infections in some users.
Officials of Genentech, a unit of Basel, Switzerland-based drugmaker Roche, are readying for a Jan. 30 jury trial in state court in California over allegations that Raptiva caused Stephen Johnson’s death. The 46-year-old Louisiana businessman took the drug to treat a skin condition. Genentech withdrew the medication from the market almost three years ago after it was linked to fatal brain infections.
“Psoriasis isn’t life-threatening and his wasn’t even that horrible,” Mark Lanier, a lawyer for Johnson’s family, said in an interview. “This drug was never about the patients. This drug was about the money.”
Monday, January 16, 2012
Roche Faces First Trial of Claims Over Raptiva Infections - Businessweek
via businessweek.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment